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Fig. S1 shows that Gag-GFP forms punctate structures at the plasma membrane, visible by fluorescence microscopy. 
Fig. S2 shows that Gag-GFP forms punctate structures at the plasma membrane, visible by fluorescence microscopy. 
Fig. S3 shows that Gag(G2A)-GFP does not form punctate structures at the plasma membrane, visible by fluorescence 
microscopy. 
Fig. S4 shows that Gag-GFP expression induces buds at the PM, visible by EM of Epon embedded yeast. 
Fig. S5 shows that Gag-GFP expression induces buds at the PM, visible by EM of Epon embedded yeast. 
Fig. S6 shows that Gag-GFP accumulates in PM buds of the WT YWO1 and SUB62, visible by EM of cryosections 
labeled with immunogold. 
Fig. S7 demonstrates that ESCRT deletion does not impair Gag-GFP-membrane binding after MET3 promoter 
induction, that Gag-GFP expressed from a 2µ vector with MET3 promoter is released from yeast spheroplasts, that 
release depends on Gag myristoylation, is reduced by ESCRT deletion, that we did not detect release when Gag-GFP 
was expressed from the ARS/CEN vector, and demonstrates with additional experiments that release of Gag-GFP 
expressed from the 2µ vector with PGK promoter is reduced by ESCRT deletion. 
Fig. S8 coimmunoprecipitation experiments, showing that Bro1 binds to CA, that Vps23 binds to NC-containing Gag 
fragments in the presence of 150 mM NaCl, that the presence of 400 mM NaCl does not alter the p6-dependent Gag 
binding to ALIX and TSG101 compared to 150 mM NaCl. 
Fig. S9 binding assays comparing different epitope tags. 
Fig. S10 shows that Gag(Δ8-87)-GFP accumulates at the PM in structures with larger diameters than Gag-GFP, visible 
by fluorescence microscopy. 
Fig. S11 shows examples of coimmunoprecipitation experiments done to characterize the MA-Bro1 interaction. 
Fig. S12 shows that Vps23 binding to MA is independent of Bro1 and vice versa. 
Fig. S13 shows that L31 or W36 mutation increases Gag-GFP-membrane binding and Gag-GFP release from yeast 
spheroplasts, that the ΔNCA mutation does not reduce Gag-GFP-membrane association and reduces Gag-GFP release, 
is dominant over MA3*, that p6 deletion does not further reduce Gag(MA3*/ΔNCA)-GFP release, and that V35E 
reduces Bro1 binding to Gag-GFP in presence of ΔNCA and p6. 
Fig. S14 shows that Gag(MA3*)-GFP forms punctate structures at the PM similar to Gag-GFP and does not form 
aggregates, visible by fluorescence microscopy. 
Fig. S15 shows that Gag(ΔNCA)-GFP forms punctate structures at the PM similar to Gag-GFP and does not form 
aggregates, visible by fluorescence microscopy. 
Fig. S16 shows PM rim staining of MA3*-GFP, visible by fluorescence microscopy. 
Fig. S17 shows PM rim staining of MA3*-GFP, visible by fluorescence microscopy. 
Fig. S18 shows that the MA3* release increasing effect depends on yeast ESCRT proteins, that Gag(ΔNCA)-GFP 
release from Δvps4 spheroplasts is slightly decreased compared to Gag-GFP, that the MA3* mutation increases Gag-
GFP release from HEK293 cells and that a combination of ΔNCA and mutation of the ALIX binding site in p6 (p6A*) 
abrogates this increase. 
Fig. S19 shows that the genomically epitope-tagged ESCRT proteins used in this study are functional. 
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Fig. S1: The intracellular localization of Gag-GFP expressed from a 2µ vector with PGK promoter in WT yeast cells 
was analyzed by fluorescence microscopy, showing that Gag-GFP accumulates in punctate structures at the PM. Two 
layers of yeast cells are shown. DIC: differential interference contrast. 
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Fig. S2: The intracellular localization of Gag-GFP expressed from a 2µ vector with PGK promoter in WT yeast cells 
was analyzed by fluorescence microscopy, showing that Gag-GFP accumulates in punctate structures at the PM. Three 
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Fig. S3: Gag(G2A)-GFP expressed from a 2µ vector with PGK promoter in WT yeast cells was analyzed by 
fluorescence microscopy, showing a cytosolic localization. Gag(G2A)-GFP accumulations in undefined structures 
were visible in approximately one third of the cells. Enhanced brightness (b). DIC: differential interference contrast. 
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Fig. S4: WT yeast cells expressing Gag-GFP from a 2µ vector with MET3 promoter (+, A.-D.) or carrying the empty 
vector (-, E.-G.) were embedded in Epon. Sections were analyzed by EM, exhibiting buds (arrows) at the PM in 
presence of Gag-GFP. Cells were grown in medium containing 20 mg/l methionine to repress the promoter. To induce 
the promoter, cells were shifted to medium lacking methionine for 6 h. Sections shown in A, B, C, F, G are derived 
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from the same experiment. A. is also shown in Fig. 1F. Sections shown in D and E are derived from a second 





Fig. S5: WT yeast cells expressing Gag-GFP from a 2µ vector with MET3 promoter (+, A.-D.) or carrying the empty 
vector (-, E) were embedded in Epon. Sections were analyzed by EM, exhibiting buds (arrows) at the PM in presence 
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of Gag-GFP. Cells were grown in medium containing 20 mg/l methionine to repress the promoter. To induce the 
promoter, cells were shifted to medium lacking methionine for 6 h. The sections are derived from one experiment that 






Fig. S6: PM deformation (arrows) induced by Gag-GFP expression was analyzed by EM. Cryosections of WT yeast 
cells (SUB62) expressing Gag-GFP from a 2µ vector with PGK promoter (A.) or of WT cells (YWO1) expressing 
Gag-GFP from a 2µ vector with MET3 promoter induced for 6 h (B.) were prepared. GFP was labeled with 
immunogold. Asterisks indicate the cell wall. A. is also shown in Fig. 1G. 
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Fig. S7: A. and B. Gag-GFP-membrane binding after MET3-promoter induction was analyzed, showing that ESCRT 
deletion does not impair Gag-membrane binding. WT cells or the indicated ESCRT mutants carrying a Gag-GFP 2µ 
expression vector with MET3 promoter were grown in medium containing 20 mg/ml methionine to repress the 
promoter. To induce the promoter, cells were shifted to medium lacking methionine. After 60, 90, 120, and 360 min 
cell extracts (B) were prepared and separated by centrifugation at 25,000g into a membrane-containing sediment (P) 
and a cytosol-containing supernatant (S) (A). The samples were analyzed by immunoblotting with anti-GFP 
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antibodies. Sec61 (ER-membrane protein) and PGK (cytosolic protein) served as references. C. and D. Gag-GFP 
release from yeast spheroplasts was analyzed by immunoblotting of high-speed centrifugation sediments derived from 
the incubation medium with anti-GFP antibodies (VLPs). GFP-tagged Gag or Gag(G2A) was expressed from a 2µ 
vector with MET3 promoter in the WT or the indicated mutants. The promoter was induced when spheroplast 
preparation started. Immunoblots with antibodies detecting PGK (cytosolic protein), Sec61 (ER-membrane protein), or 
Emp47 (Golgi and COPII membrane protein) served as control for specific Gag release. S: lysate of spheroplasts 
prepared at the final VLP harvest. C. Showing myristoylation-dependent release. The first VLP harvest after 2-h 
incubation is not shown. D. Showing ESCRT-dependent release. E. Same as above except that Gag-GFP was 
expressed from a 2µ vector or an ARS/CEN vector with MET3 promoter, showing that VLPs cannot be harvested 
from spheroplasts expressing Gag-GFP from the ARS/CEN vector. The promoter was induced during yeast 
cultivation. F.-H. Same as above except that Gag-GFP was expressed from a 2µ vector with PGK promoter in the WT 






Fig. S8: A. and B. Coimmunoprecipitation experiments with GFP-tagged Gag or Gag fragments expressed from a 2µ 
vector with induced MET3 promoter in yeast strains carrying genomically epitope-tagged Bro1 or Vps23. Gag or Gag 
fragments were immunoprecipitated with anti-GFP antibodies and coimmunoprecipitated Bro1 or Vps23 was detected 
by immunoblotting with antibodies against the epitope tag. MA (aa 1-132), CA (aa 133-363), p6 (aa 448–500), CA-
SP1-NC-SP2 (aa 133–447), SP1-NC-SP2 (aa 364-447), SP1-NC-SP2-p6 (aa 364–500). A. Showing that Bro1 binds to 
CA. In the presence of 400 mM NaCl. B. In the presence of 150 mM NaCl, showing that Vps23 coprecipitates with an 
NC-containing fragment under these salt conditions. C. and D. Coimmunoprecipitations of epitope-tagged ALIX or 
TSG101 with GFP-tagged Gag versions expressed from CMV-promoter vectors in HEK293 cells, showing that ALIX 
binding to Gag is reduced but not prevented by p6 deletion. TSG101 binding to Gag-GFP more strongly depends on 
p6. GFP-tagged proteins were immunoprecipitated with anti-GFP antibodies in the presence of 400 mM NaCl and 
coimmunopreciptated ALIX or TSG101 was detected with antibodies recognizing the epitope tag. 
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Fig. S9: Binding assays comparing different epitope tags. A.–D. GST-tagged Gag fragments (MA (aa 1-132), CA (aa 
133-363), p6 (aa 448-500)) expressed in E.coli were bound to Glutathione Sepharose and incubated with extract of 
yeast cells carrying genomically epitope-tagged Bro1. The binding buffer contained 400 mM NaCl. Bead-bound 
proteins were analyzed by immunoblotting with the indicated antibodies. PGK served as control, showing specific 
Bro1 binding. P6T*: mutated TSG101 binding site, p6A*: mutated ALIX binding site. A. Fig. 3I shown for 
comparison. D. Fig. 3H with additional exposures shown for comparison. E.–F. Gag-GFP or MA-GFP was expressed 
from a 2µ vector with induced MET3 promoter in yeast strains carrying genomically epitope-tagged Bro1. GFP-
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tagged proteins were immunoprecipitated with anti-GFP antibodies and coimmunoprecipitated Bro1 was detected by 
immunoblotting with anti-HA or anti-Myc antibodies. A long (a) and a short (b) exposure are shown. G.–J. GST-
tagged MA or p6 expressed in E.coli was bound to Glutathione Sepharose and incubated with extract of HEK293 cells 
expressing epitope-tagged ALIX or TSG101 from a CMV-promoter vector in the presence of 150 mM NaCl. Bead-






	   S-12 
 
 
Fig. S10: Gag(Δ8-87)-GFP or Gag-GFP expressed from a 2µ vector with PGK promoter in WT yeast cells was 
analyzed by fluorescence microscopy. Compared to Gag-GFP, Gag(Δ8-87)-GFP forms fewer structures at the PM 
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Fig. S11: Examples of coimmunoprecipitation experiments that were done to characterize the MA-Bro1 interaction. 
GFP-tagged Gag, Gag fragments, or MA (aa 1-132) versions were expressed from a 2µ vector with induced MET3 
promoter in yeast cells carrying genomically 3HA-tagged Bro1. GFP-tagged proteins or peptides were 
immunoprecipitated with anti-GFP antibodies in the presence of 400 mM NaCl and coimmunoprecipitated Bro1 was 
detected by immunoblotting with anti-HA antibodies. A.-C. With MA fragments or internal-deletion mutants, 
indicating that helix-2 (aa 30-43) and the strand loop between helix-1 and 2 (aa 20-29) might be involved in the MA-
Bro1 interaction. Secondary structural-element assignments are derived from the MA x-ray structure (11). D.-F. AAA-
scanning mutagenesis for MA residues 20 to 43, showing that YKL29,30,31AAA and VWA35,36,37AAA reduce the 
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Fig. S12: A.-C. Coimmunoprecipitation experiments with GFP-tagged Gag or MA (aa 1-132) expressed from a 2µ 
vector with induced MET3 promoter in yeast strains carrying genomically 9Myc-tagged Vps23 or Bro1. Gag or MA 
was immunoprecipitated with anti-GFP antibodies and coimmunoprecipitated Vps23 or Bro1 was detected by 
immunoblotting with anti-Myc antibodies in the presence of 400 mM NaCl. A. With WT yeast cells or the indicated 
mutants, showing that Vps23 coimmunoprecipitated with Gag independent of Bro1. Bro1 coimmunoprecipitated with 
Gag expressed in a Δvps23 mutant. Because Gag expression was reduced in this strain, the coimmunoprecipitated 
Bro1 amount cannot be directly compared with that precipitated from the WT strain. B. With WT yeast cells or a 
Δvps23 mutant, showing that Bro1 coimmunoprecipitated with MA in absence of Vps23. Same problem as in A. C. 
With WT yeast cells or the indicated mutants, showing that Vps23 coimmunoprecipitated with Gag and MA in 
absence of Bro1 or Vps27, another ubiquitin-binding ESCRT protein. D. and E. Pull-down experiments, showing that 
genomically 9Myc-tagged Bro1 or Vps23 bound to GST-MA expressed in E. coli while VPS23 or BRO1 was deleted. 
GST-MA (aa 1-132) was bound to Glutathione Sepharose and incubated with yeast extract in the presence of 150 mM 
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Fig. S13: A.-C. Membrane-containing 25,000g pellets (P) and cytosol-containing supernatants (S) derived from cell 
extracts (T) were analyzed by immunoblotting with the indicated antibodies, showing that L31 or W36 mutations 
increase Gag-membrane binding and that the ΔNCA mutation does not reduce Gag-membrane association. The 
cytosolic protein GAPDH and the integral ER-membrane protein Sec61 served as references. D.-I. Release of Gag-
GFP versions from WT yeast spheroplasts was analyzed by immunoblotting of high-speed centrifugation sediments 
derived from the incubation medium with anti-GFP antibodies (VLPs). S: lysate of spheroplasts prepared at the final 
VLP harvest. D.-H. Showing that MA mutations in L31 and W36 increase Gag release. I. Showing that ΔNCA 
reduces Gag release, is dominant over MA3*, and that p6 deletion does not further reduce Gag(MA3*/ΔNCA) release. 
A.-I. Gag-GFP versions were expressed from a 2µ vector with PGK promoter in WT yeast. Long (a) and short (b) 
exposures are shown. J. Coimmunoprecipitation experiment with Gag-GFP versions expressed from a 2µ vector with 
induced MET3 promoter in yeast cells carrying genomically 9Myc-tagged Bro1, showing that although V35E does not 
reduce the Gag-Bro1 coimmunoprecipitation, the Bro1 amount that coimmunoprecipitates with 
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Gag(V35E/ΔNCA/Δp6)-GFP is reduced compared to Gag(ΔNCA/Δp6)-GFP. Gag was immunoprecipitated with anti-
GFP antibodies in the presence of 400 mM NaCl and coimmunoprecipitated Bro1 was detected by immunoblotting 
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Fig. S14: Gag(MA3*)-GFP expressed from a 2µ vector with PGK promoter in WT yeast cells was analyzed by 
fluorescence microscopy, showing that Gag(MA3*)-GFP forms punctate structures at the PM similar to Gag-GFP 
(Fig. S1, S2) and does not form aggregates. DIC: differential interference contrast. 
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Fig. S15: Gag(ΔNCA)-GFP expressed from a 2µ vector with PGK promoter in WT yeast cells was analyzed by 
fluorescence microscopy, showing that Gag(ΔNCA)-GFP forms punctate structures at the PM similar to Gag-GFP 
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Fig. S16: MA3*-GFP expressed from a 2µ vector with PGK promoter in WT yeast cells was analyzed by fluorescence 
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Fig. S17: MA3*-GFP expressed from a 2µ vector with PGK promoter in WT yeast cells was analyzed by fluorescence 
microscopy, showing PM rim staining. DIC: differential interference contrast, b: enhanced brightness. 
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Fig. 18: Gag-GFP release from yeast spheroplasts was analyzed by immunoblotting of high-speed centrifugation 
sediments derived from the incubation medium with anti-GFP antibodies (VLPs). Gag-GFP versions were expressed 
from a 2µ vector with PGK promoter in the WT or the indicated mutants. S: lysate of spheroplasts prepared at the final 
VLP harvest. Long (a) and short (b) exposures are shown. A.-D. Δvps23Δbro1 nearly abolished the MA3* effect after 
5 and 7 h of incubation. C., E.-G. Gag(MA3*)-GFP release from Δbro1 spheroplasts was increased compared to Gag-
GFP in 2 experiments (C. and E.), whereas the MA3* effect was abolished in two other experiments (F. and G.). D., 
H. –J. Gag(MA3*)-GFP release from Δvps23 spheroplasts was increased compared to Gag-GFP. K. and L. Δvps4 
abolished the MA3* effect. M. Gag(ΔNCA)-GFP release from Δvps4 spheroplasts was slightly decreased compared to 
Gag-GFP. N. Gag-GFP release from HEK293 cells 2 d after transfection with CMV-promoter expression vectors for 
the indicated Gag versions. VLPs were harvested from the culture medium and cell lysates were prepared. Gag-GFP 
was detected by immunoblotting with anti-GFP antibodies. Several exposures (a,b,c) are shown. The MA3* mutation 
increased Gag-GFP release. A combination of ΔNCA and mutation of the ALIX binding site in p6 (p6A*) abrogated 
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Fig. S19: Bro1-3HA, Bro-9Myc, and Vps23-9Myc are functional in the CPS-transport assay. A.–C. The vacuolar 
processing of N-terminally GFP-tagged carboxypeptidase S (GFP-CPS) was analyzed in yeast strains carrying 
genomically epitope-tagged ESCRT proteins (31, 129). D. CPS is a soluble vacuolar enzyme that is synthesized as a 
precursor type II transmembrane protein, transported to the vacuolar interior by the MVB pathway, and cleaved from 
its transmembrane anchor by vacuolar hydrolases. In GFP-CPS transport, the GFP moiety is initially located on the 
cytosolic side of the endosomal membrane, GFP-CPS is sorted into MVB vesicles and transported into the endosomal 
interior. After endosome-vacuole fusion, vacuolar enzymes degrade the vesicles and release free GFP and CPS. In 
ESCRT knockout mutants, MVB vesicle formation is impaired and GFP-CPS accumulates in the limiting endosomal 
and vacuolar membranes. After proteolytic processing, GFP remains connected to the short cytosolic and 
transmembrane domain of CPS (GFP-TM). A.–C. Lysate of WT cells, ESCRT knockout mutants, or strains with 
genomically epitope-tagged Bro1 or Vps23 carrying a GFP-CPS expression plasmid were analyzed by 
immunoblotting with the indicated antibodies. PGK served as loading control. Short (a) and long (b) exposures are 
shown. #, *: signal of Protein A (ProA) reactivity with antibodies used for the detection of other epitope tags. PAP: 
peroxidase-anti-peroxidase complex. 
Yeast cells were disrupted with glass beads in 50 mM Tris (pH 7.5) and 1% SDS containing protease inhibitors. The 
lysates were cleared by centrifugation (10 min, 16,000g). 
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MATα, trp-1(am), his3-Δ200, ura3-52, lys2-801, leu2-3, -
112	  
Ref. 136 
YBM87 MATα, vps23::HIS3, trp-1(am), his3-Δ200, ura3-52, lys2-
801, leu2-3, -112	  
this study 
YBM88 MATα, bro1::KanMX6, trp-1(am), his3-Δ200, ura3-52, 
lys2-801, leu2-3, -112	  
this study  
YBM89 MATα, vps23::HIS3, bro1::KanMX6, trp-1(am), his3-
Δ200, ura3-52, lys2-801, leu2-3, -112 
this study 
YBM90 MATα, vps4::HIS3, trp-1(am), his3-Δ200, ura3-52, lys2-
801, leu2-3, -112 
this study 
YBM91 MATα, vps20::HIS3, trp-1(am), his3-Δ200, ura3-52, lys2-
801, leu2-3, -112 
this study 
YBM92 MATα, vps27::HIS3, trp-1(am), his3-Δ200, ura3-52, lys2-
801, leu2-3, -112 
this study 
YBM93 MATα, vps28::HIS3, trp-1(am), his3-Δ200, ura3-52, lys2-
801, leu2-3, -112 
this study 
YBM94 MATα, Bro1-3HA:HIS3, trp-1(am), his3-Δ200, ura3-52, 
lys2-801, leu2-3, -112	  
this study 
YBM95 MATα, Bro1-9Myc:TRP1, trp-1(am), his3-Δ200, ura3-52, 
lys2-801, leu2-3, -112 
this study 
YBM96 MATα, Vps23-9Myc:TRP1, trp-1(am), his3-Δ200, ura3-
52, lys2-801, leu2-3, -112	  
this study 
YBM97 MATα, Bro1-9Myc:TRP1, vps23::KanMX6, trp-1(am), 
his3-Δ200, ura3-52, lys2-801, leu2-3, -112 
this study 
YBM98 MATα, Vps23-9Myc:TRP1, bro1::KanMX6, trp-1(am), 
his3-Δ200, ura3-52, lys2-801, leu2-3, -112 
this study 
YBM99 MATα, Vps23-9Myc:TRP1, vps27::KanMX6, trp-1(am), 
his3-Δ200, ura3-52, lys2-801, leu2-3, -112 
this study 
SUB62 MATa, trp1-1(am), his3-Δ200, ura3-52, lys2-801, leu2-
3,112 
Ref. 137 
	  
 
